Form 8-K - Current report:
SEC Accession No. 0000950170-25-003286
Filing Date
2025-01-08
Accepted
2025-01-08 08:00:09
Documents
13
Period of Report
2025-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K trvi-20250108.htm   iXBRL 8-K 57596
2 EX-99.1 trvi-ex99_1.htm EX-99.1 25191
3 GRAPHIC img251553556_0.jpg GRAPHIC 29443
  Complete submission text file 0000950170-25-003286.txt   249895

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT trvi-20250108.xsd EX-101.SCH 28532
15 EXTRACTED XBRL INSTANCE DOCUMENT trvi-20250108_htm.xml XML 4711
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38886 | Film No.: 25516602
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)